Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 EMD Millipore Adds Clone Generation Service | Contract Pharma

What are you searching for?

Sign in
Breaking News

EMD Millipore Adds Clone Generation Service

Expands Provantage biodevelopment services

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, has expanded its Provantage Biodevelopment Services to include a Clone Generation Service.
 
The new service includes expression of recombinant proteins such as hormones, growth factors and mono- and bi-specific monoclonal antibodies. Customers can choose from DG44 and CHO-S cell lines, both of which are widely used for high-yield production of biologics. Every clone generation is fully documented to ensure traceability from the source and demonstrate that the cell is clonal, making the cells usable for clinical production, IND submission.
 
“Development of a high-quality, high-expressing cell line is a critical, early step in the production of a biologic drug,” said Udit Batra, president and chief executive officer of EMD Millipore. “The cell line not only defines the product, but also drives much of the yield and titer during bioproduction. Our Provantage team and services optimize clone generation as well as the entire clinical scale process, setting the stage for manufacturing success.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics